Welcome to our dedicated page for Quantum Biopharma news (Ticker: QNTM), a resource for investors and traders seeking the latest updates and insights on Quantum Biopharma stock.
Quantum BioPharma Ltd. (QNTM) generates news across clinical development, capital markets, licensing, and legal proceedings, reflecting its role as a biopharmaceutical company focused on neurodegenerative and metabolic disorders and alcohol misuse disorders. Many of its recent announcements center on Lucid-21-302 (Lucid-MS), a patented new chemical entity developed through its subsidiary Lucid Psycheceuticals Inc. News items describe progress in toxicity and toxicokinetic studies, Phase 1 clinical work, and preparations for an Investigational New Drug (IND) application with the U.S. FDA, as well as a joint PET imaging study with Massachusetts General Hospital scientists to monitor myelin integrity in multiple sclerosis.
Investors following QNTM news will also see updates on financial results, balance sheet developments, and capital structure changes, including private placements, warrant expirations, at-the-market offering agreements, and the issuance of contingent value rights (CVRs) linked to potential recoveries from litigation. The company’s disclosures highlight its digital asset portfolio, comprised mainly of Bitcoin and other cryptocurrencies, and provide commentary on realized gains and treasury management.
Another recurring theme in Quantum BioPharma’s news flow is its relationship with Unbuzzd Wellness Inc., licensee of the unbuzzd asset. Press releases cover Unbuzzd Wellness Inc.’s capital raising plans, investor webinars, and positioning of unbuzzd as a beverage or supplement aimed at alcohol metabolism and related symptoms, while noting Quantum BioPharma’s equity stake and royalty rights.
In addition, Quantum BioPharma issues updates on its lawsuit alleging stock market manipulation and stock spoofing involving major financial institutions, including coverage by investigative news program W5. These items outline the company’s allegations, the scale of the claimed damages, and the link between the litigation and the CVR structure. For readers and investors, the QNTM news stream offers a consolidated view of clinical milestones, financial reporting, licensing activity, and legal developments related to Quantum BioPharma.
Quantum BioPharma (QNTM) announced that Rodman & Renshaw has initiated analyst coverage with a BUY rating and a US$8 price target.
The initiation research report is led by Michael G. King Jr., Director of Research and Senior Biotechnology Analyst at Rodman & Renshaw. The company states that the coverage is unpaid, with Quantum BioPharma providing no consideration or fees for the report. A copy of the initiation report is available through the referenced “Quantum Published Initiation Report.”
Quantum BioPharma (QNTM) will present at the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto on September 16, 2026.
The company will discuss recent milestones, including U.S. FDA approval of its Investigational New Drug application for Lucid-MS, enabling initiation of Phase 2 trials in patients with progressive multiple sclerosis, an area the company describes as a substantial unmet medical need. Lucid-MS is a patented new chemical entity investigational candidate designed to provide neuroprotection by inhibiting demyelination and targeting underlying neurodegeneration.
Quantum also highlights its economics from UNBUZZD™, retaining a 19.48% ownership stake in Unbuzzd Wellness as of June 30, 2026 and a royalty stream of 7% of unbuzzd™ sales until cumulative payments reach $250 million, after which the royalty declines to 3% in perpetuity, while keeping 100% of rights for pharmaceutical and medical formulations.
Quantum BioPharma (QNTM) received FDA clearance to begin a phase 2 clinical trial of Lucid-MS in patients with multiple sclerosis. The candidate is described as a patented, first-in-class therapy designed to protect and potentially rebuild the myelin sheath, targeting the underlying mechanism of MS rather than immune suppression. This would be the first human MS trial for a drug using this specific mechanism, and the milestone has already attracted a new buy rating from Wall Street analysts, according to the company. Quantum’s Lucid-MS program is advanced through wholly owned subsidiary Lucid Psycheceuticals.
Quantum also highlights its economic interest in UNBUZZD(TM), holding 19.84% of Unbuzzd Wellness and entitled to a 7% royalty on unbuzzd(TM) sales until cumulative payments reach $250 million, after which royalties decline to 3% in perpetuity.
Quantum BioPharma (QNTM) has received FDA clearance to begin a phase 2 clinical trial of Lucid-MS, a patented, first-in-class multiple sclerosis drug candidate focused on protecting and potentially repairing the myelin sheath rather than modulating the immune system.
The company states this will be the first time a drug using this specific mechanism is tested in people living with MS, and notes that the milestone has already attracted a new buy rating from Wall Street analysts. Lucid-MS, developed via subsidiary Lucid Psycheceuticals, has shown prevention and reversal of myelin degradation in preclinical models. Quantum also highlights economic interests in UNBUZZD(TM), retaining 19.84% ownership in Unbuzzd Wellness and a royalty on unbuzzd(TM) sales, starting at 7% until cumulative payments reach $250 million, then 3% in perpetuity.
Quantum BioPharma (NASDAQ/CSE: QNTM) reported Q2 2026 results showing stronger liquidity and a key regulatory advance for its lead MS program. As of June 30, 2026, combined cash, cash equivalents and digital assets were approximately US$9.5 million, up from US$4.1 million at December 31, 2025, with cash alone rising to US$3.65 million. Total shareholders’ equity increased about 19% to US$6.09 million, and working capital improved to roughly US$1.66 million. Management expects this liquidity to fund planned operations at least to October 2027, assuming a cash burn rate similar to the first half of 2026.
Operating expenses fell 53% year-over-year in Q2 to US$2.29 million, with G&A down 47%, and cash used in operating activities for the first half down 44% to US$3.46 million. According to Quantum, the FDA has approved its IND for Lucid-MS, enabling a randomized, double-blind, placebo-controlled Phase 2 trial in progressive multiple sclerosis. Quantum also highlights its 19.48% stake and tiered royalty agreement with Unbuzzd Wellness for UNBUZZD™.
Quantum BioPharma (NASDAQ: QNTM) reported that the U.S. FDA has cleared its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), allowing the company to proceed to a randomized, double-blind, placebo-controlled Phase 2 trial in progressive multiple sclerosis (MS).
Lucid-MS is a patented, first-in-class, non-immunomodulatory investigational therapy designed to provide neuroprotection by inhibiting demyelination through targeting PAD2, and previously showed a favorable safety profile in Phase 1 studies. Quantum BioPharma is partnering with a global clinical research organization to execute the trial, with site selection underway and enrollment planned as soon as feasible. The company reported over USD $10 million in cash, digital assets and liquid investments as of March 31, 2026 to support clinical development.
Quantum BioPharma (NASDAQ: QNTM) highlighted its development of Lucid-MS, a patented, first-in-class multiple sclerosis (MS) drug candidate. Lucid-MS targets the myelin sheath damaged in MS and is preparing to enter phase 2 clinical trials.
MS affects more than 2.9 million people globally, with no cure and existing treatments unable to fully stop disease progression.
Quantum BioPharma (NASDAQ: QNTM) announced that its MS drug candidate Lucid-MS, described as patented and first-in-class, is preparing to enter phase 2 clinical trials. The therapy takes a different approach by directly targeting the myelin sheath damaged in multiple sclerosis, a disease affecting over 2.9 million people worldwide.
Quantum BioPharma (NASDAQ: QNTM) entered a 6‑month investor relations and consulting agreement with Stocks.news via IR Agency LLC, starting June 8, 2026, for a US$250,000 fee.
The Agency will handle company profiles, media and news distribution, digital community building, and lead generation. It is arm’s‑length and holds no equity in Quantum.
Quantum BioPharma (NASDAQ: QNTM) reported a key midpoint milestone in its collaborative PET imaging study with Massachusetts General Hospital, with patient enrollment at 50% and encouraging preliminary imaging data.
The study uses novel tracer [¹⁸F]3F4AP to quantify demyelination in multiple sclerosis and support development of Quantum’s investigational therapy Lucid-MS, which showed favorable Phase 1 safety and preclinical myelin-protective effects. An IND for a Phase 2 trial was submitted to the FDA in March 2026.